<DOC>
	<DOCNO>NCT00463151</DOCNO>
	<brief_summary>The purpose study examine safety efficacy rebamipide daily intracolonial administration 0 ( placebo ) , 60 , 150 , 300 mg 6 week patient active ulcerative colitis , treat oral aminosalicylic acid ( ASA ) .</brief_summary>
	<brief_title>An Exploratory Study Rebamipide Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>1 . Patients active ulcerative colitis 2 . Patients insufficient response ASA oral formulation : ( 1 ) Patients whose ongoing use ASA oral formulation ≥2 week prior day registration fix mesalazine ≥2 g/day salazosulfapyridine 36 g/day , ( 2 ) Patients continuous bloody stool ≥2 week prior day registration , ( 3 ) Patients whose DAI subscores ≥2 point `` bloody stool '' ≥2 point `` endoscopic finding '' 3 . Patients show via colonoscopy major lesion sigmoid colon rectum ( lesion extend beyond splenic flexure ) 4 . Outpatients 1 . Patients history intestinal resection ( appendiceal resection ) 2 . Patients complication malignant tumor 3 . Female patient pregnant , lactate , possibly pregnant , hope become pregnant study period 4 . Patients complication serious cardiac , hepatic renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Rebamipide</keyword>
	<keyword>Enema</keyword>
	<keyword>Ulcerative Colitis</keyword>
</DOC>